NCT02205476View on ClinicalTrials.gov

A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Hypertrophic Scars Resulting From Prior Breast Scar Revision Surgery
Interventions
DRUG

PF-06473871

Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.

DRUG

PF-06473871

Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.

Trial Locations (5)

30328

Kavali Plastic Surgery and Skin Renewal Center, Atlanta

Primeter outpatient surgery center, Atlanta

33133

Bayside Ambulatory Center, Miami

33146

Stephan Baker MD PA, Coral Gables

63141

Body Aesthetic Research Center, St Louis

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02205476 - A Phase 2 Extension Study To Enroll Subjects Who Were Enrolled In B5301001 Study | Biotech Hunter | Biotech Hunter